Study of the Inflammatory Microenvironment in Atypical Meningiomas

Atypical Meningioma Clinical Trial

Official title:

Prognostic Impact of the Inflammatory Microenvironment in Atypical Meningiomas

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04761653
• Other study ID #: 2021PI015
• Status: Recruiting
• Start date: January 1, 2021
• Est. completion date: June 30, 2021

Study information

• Verified date: February 2021
• Source: Central Hospital, Nancy, France
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Atypical meningiomas represent 15% of meningiomas. They present a high rate of recurrence, and therapeutic strategies are limited. There is a need for novel treatment strategies, such as immuotherapy.

This is a retrospective study including 84 patients with primary diagnosis of atypical meningiomas. The presence of T cells (CD4, CD8, Treg and memory T cells) and mature dendritic cells will be quantified on whole tissue sections stained by immunohistochemistry (CD4, CD8, FOXP3, CD45RO and CD208).

This could allow us to identify novel biomarkers for survival, and facilitate the selection of patients who may benefit from immunotherapeutic modalities.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 84
• Est. completion date: June 30, 2021
• Est. primary completion date: June 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• primary diagnosis of atypical meningioma

• surgery

Related Conditions & MeSH terms

• Atypical Meningioma
• Meningioma

Locations

Country	Name	City	State
France	Guillaume GAUCHOTTE	Vandoeuvre Les Nancy

Sponsors (1)

Lead Sponsor	Collaborator
Central Hospital, Nancy, France

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression free survival		2-21 years
Secondary	Overall survival		2-21 years